Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 01/01/1970 12:00 am ...

AbbVie Inc. (NYSE:ABBV) shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share ...

Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Other drugs in AbbVie's lineup, including Botox, migraine therapies Qulipta and Ubrelvy, cancer drug Venclexta, and antipsychotic medication Vrayalar, are also delivering strong sales growth.

Three Motley Fool contributors have identified some especially great high-yield dividend stocks to buy in 2025 -- and all of them are big pharma stocks. Here's why they chose AbbVie(NYSE: ABBV), Amgen ...

The oral Nurtec (rimegepant) and Qulipta (atogepant) drugs are also considered first-line preventive care for migraine symptoms. Additionally, Nurtec, Ubrelvy (ubrogepant), and Zavzpret (zavegepant)—a ...

But a recently approved daily migraine pill called Qulipta (atogepant) appears to be effective from day one in many patients, clinical trial data shows. Patients taking Qulipta had a 37% to 61% ...